|
| Rank | Cases or methods that achieved consensus agreement ((%) of agreement) |
|
| | Optimal patient profiles: selection of safinamide based on history of receiving other MAO-B inhibitors (Q4) |
| 1 | Can become a treatment option in MAO-B inhibitor-naïve patients (97.8%) |
| 2 | Can become a treatment option in patients in whom the efficacy of other MAO-B inhibitors was not sufficient in the past (95.7%) |
| 3 | Can become a treatment option in patients who previously experienced adverse events related to other MAO-B inhibitors (91.3%) |
|
| | Treatment methods: patients for whom safinamide should be administered after carefully balancing risks and benefits of treatment (Q7) |
| 1 | Experienced hallucinations or drug-induced hallucinations (93.5%) |
| 2 | Concerns of impulse control disorder (87.0%) |
| 3 | High blood pressure variability (82.6%) |
|
| | Treatment methods: cases in which dose increase to 100 mg/day is recommended (Q10) |
| 1 | Insufficient improvement of symptoms and difficulty in dose increase of other medication (97.8%) |
| 2 | Insufficient effect of another MAO-B inhibitor at the approved dose (97.8%) |
| 3 | Non-motor symptoms that affect daily life (93.5%) |
|
| | Treatment methods: cases in which dose reduction or discontinuation is required (Q11) |
| 1 | No improvement in symptoms (97.8%) |
| 2 | Occurrence of adverse reactions (hallucination, sleepiness, orthostatic hypotension) (95.7%) |
| 3 | Requirement for use of anti-depressants (95.7%) |
|
| | Treatment methods: safinamide use in elderly (aged ≥ 75 years) patients with Parkinson’s disease (Q8) |
| 1 | Adopt the same usage and cautions as in non-elderly patients (100.0%) |
| 2 | Be careful of the occurrence of psychiatric symptoms, hallucination, or visual hallucination (97.8%) |
| 3 | Confirm the degree of hepatic toxicity (95.7%) |
| 4 | Dose increase is possible if there is no concern of tolerability (95.7%) |
| 5 | Initial dose should be 50 mg/day (93.5%) |
|
